Istari Oncology, Inc.
13
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.8%
4 terminated/withdrawn out of 13 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
133%
8 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Role: lead
Lerapolturev (PVSRIPO) in GBM
Role: collaborator
Lerapolturev in Recurrent Malignant Glioma
Role: lead
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Role: lead
D2C7-IT With Atezolizumab for Recurrent Gliomas
Role: collaborator
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Role: lead
PVSRIPO for Patients With Unresectable Melanoma
Role: lead
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Role: lead
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
Role: lead
PVSRIPO for Recurrent Glioblastoma (GBM)
Role: lead
EAP for the Treatment of Glioblastoma With PVSRIPO
Role: lead
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
Role: collaborator
PVSRIPO in Combination With Nivolumab in Melanoma
Role: collaborator
All 13 trials loaded